Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bio-Rad Laboratories's Enterprise Value is €5,414 Mil.
Bio-Rad Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was €-2,558 Mil. Therefore, Bio-Rad Laboratories's EV-to-EBIT ratio for today is -2.12.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Bio-Rad Laboratories's Enterprise Value is €5,414 Mil.
Bio-Rad Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was €-2,416 Mil. Therefore, Bio-Rad Laboratories's EV-to-EBITDA ratio for today is -2.24.
Bio-Rad Laboratories Enterprise Value Historical Data
The historical data trend for Bio-Rad Laboratories's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bio-Rad Laboratories's Enterprise Value
For the Medical Devices subindustry, Bio-Rad Laboratories's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Bio-Rad Laboratories's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (STU:BUWA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Bio-Rad Laboratories's current Enterprise Value is €5,414 Mil.
Bio-Rad Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2,558 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Bio-Rad Laboratories's current Enterprise Value is €5,414 Mil.
Bio-Rad Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2,416 Mil.
Bio-Rad Laboratories's current Enterprise Value is €5,414 Mil.
Bio-Rad Laboratories's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,357 Mil.
Bio-Rad Laboratories's current Enterprise Value is €5,414 Mil.
Bio-Rad Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €307 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories Enterprise Value Related Terms
Thank you for viewing the detailed overview of Bio-Rad Laboratories's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:BUWA has been successfully added to your 